Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

clinical trial

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT04746963

P6099clinical trial phasephase I clinical trialQ5452194
phase II clinical trialQ42824440
P17countryUnited States of AmericaQ30
P582end time2022-08-01
P921main subjecteye diseaseQ3041498
P1050medical conditionmacular degenerationQ27429789
P2899minimum age50
P1132number of participants18
P8005research subject recruitment statusrecruitingQ76649708
P1813short nameSHASTA
P580start time2021-02-01
P8363study typeinterventional studyQ78089383
P1476titlePhase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Search more.